Atara Biotherapeutics (ATRA) Enterprise Value (2014 - 2026)

Atara Biotherapeutics (ATRA) has reported Enterprise Value for 13 consecutive years, with $156.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 117.19% year-over-year to $156.0 million; the trailing twelve-month figure through Jun 2026 stood at $156.0 million (up 117.19% YoY), and the FY2025 full-year result was $218.4 million, up 282.06% from the prior year.
• Enterprise Value improved to $156.0 million in Q2 2026 per ATRA's latest filing, from $58.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at $565.9 million in Q1 2022 and bottomed at -$6.5 million in Q3 2024.
• Historically, Enterprise Value has averaged $117.2 million across 5 years, with a median of $65.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value sank 113.4% in 2024, then jumped 2883.49% in 2025.
• Over 5 years, Enterprise Value stood at $71.8 million in 2022, then plunged by 96.02% to $2.9 million in 2023, then surged by 1898.21% to $57.2 million in 2024, then soared by 282.06% to $218.4 million in 2025, then declined by 28.57% to $156.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $156.0 million, $58.2 million, and $218.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.